Long-Term Efficacy of Induction Therapy With Anti-Interleukin-2 Receptor Antibodies or Thymoglobulin Compared With No Induction Therapy in Renal Transplantation

Transplantation Proceedings

Volumn 40, Issue 10, 2008, Pages 3401-3407

  Taber, D J ^a   Weimert, N A ^a   Henderson, F ^b   Lin, A ^b   Bratton, C F ^b   Chavin, K D ^b   Baliga, P K ^b  

^a MEDICAL UNIVERSITY OF SOUTH CAROLINA   (United States)

^b Division of Transplant Surgery   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BASILIXIMAB; CREATININE; CYCLOSPORIN A; DACLIZUMAB; EVEROLIMUS; IMMUNOGLOBULIN; INTERLEUKIN 2 RECEPTOR ANTIBODY; METHYLPREDNISOLONE; MYCOPHENOLIC ACID; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PREDNISONE; RAPAMYCIN; TACROLIMUS; THYMOCYTE ANTIBODY;

ACUTE GRAFT REJECTION; ADJUVANT THERAPY; ADULT; ARTICLE; CLINICAL PROTOCOL; CONTROLLED STUDY; CREATININE BLOOD LEVEL; DELAYED GRAFT FUNCTION; DEMOGRAPHY; DRUG EFFICACY; FEMALE; GRAFT FAILURE; GRAFT SURVIVAL; HUMAN; IMMUNOREACTIVITY; IMMUNOSUPPRESSIVE TREATMENT; KIDNEY GRAFT REJECTION; KIDNEY TRANSPLANTATION; LONG TERM CARE; MAJOR CLINICAL STUDY; MALE; MULTIVARIATE ANALYSIS; PRIORITY JOURNAL; RETROSPECTIVE STUDY; SURVIVAL RATE; SURVIVAL TIME;

ADULT; ANTIBODIES, MONOCLONAL; CREATININE; FEMALE; HUMANS; IMMUNOGLOBULIN G; IMMUNOSUPPRESSION; IMMUNOSUPPRESSIVE AGENTS; INTERLEUKIN-2 RECEPTOR ALPHA SUBUNIT; KIDNEY TRANSPLANTATION; MALE; MIDDLE AGED; RECEPTORS, INTERLEUKIN-2; RECOMBINANT FUSION PROTEINS; RETROSPECTIVE STUDIES; TREATMENT OUTCOME;

EID: 57549096360     PISSN: 00411345     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.transproceed.2008.08.130     Document Type: Article

References (17)

1. Mourad G., Rostaing L., Legendre C., et al. Sequential protocols using basiliximab versus antithymocyte globulins in renal-transplant patients receiving mycophenolate mofetil and steroids. Transplantation 78 (2004) 584
2. Sheashaa H.A., Bakr M., Ismail A.M., et al. Basiliximab reduces the incidence of acute cellular rejection in live-related-donor kidney transplantation: a three-year prospective randomized trial. J Nephrol 16 (2003) 393
3. Nashan B. Antibody induction therapy in renal transplant patients receiving calcineurin- inhibitor immunosuppressive regimens: a comparative review. Biodrugs 19 (2005) 39
4. Bunnapradist S. Clinical transplants. Multivariate analyses of antibody induction therapies. In: Cecka T.P. (Ed). Clinical transplants (2003), UCLA Tissue Typing Lab, Los Angeles
5. Brennan D.C., Daller J.A., Lake K.D., et al. Rabbit antithymocyte globulin versus basiliximab in renal transplantation. N Engl J Med 355 (2006) 1967
6. Lacha J., Simova M., Noskova M., et al. Zenapax versus OKT-3 prophylaxis in immunologically high-risk kidney transplant recipients. Transplant Proc 33 (2001) 2273
7. Mariat C.A., Afiani A., Alamartine E., et al. A pilot study comparing basiliximab and anti-thymocyte globulin as induction therapy in sensitized renal allograft recipients. Transplant Proc 33 (2001) 3192
8. Gonzalez E., Guitierrez E., Hernandez E., et al. Anti-CD25 monoclonal antibody sequential immunosuppressive induction therapy in renal transplants with high risk of delayed graft function. Transplant Proc 37 (2005) 3736
9. Hariharan S. Long-term kidney transplant survival. Am J Kidney Dis 38 6 (2001) 544
10. Bumgardner G.L., Hardie I., Johnson R.W., et al. Results of 3-year phase III clinical trials with daclizumab prophylaxis for prevention of acute rejection after renal transplantation. Transplantation 72 (2001) 839
11. Sheashaa H.A., Bakr M.A., Ismail A.M., et al. Long- term evaluation of basiliximab induction therapy in live donor kidney transplantation: a five-year prospective randomized study. Am J Nephrol 25 (2005) 221
12. Hardinger K.L., Schnitzler M.A., Miller B., et al. Five-year follow-up of Thymoglobulin versus ATGAM induction in adult renal transplantation. Transplantation 78 (2004) 136
13. Heilman R.L., Reddy K.S., Mazu M.J., et al. Acute rejection risk in kidney transplant recipients on steroid-avoidance immunosuppression receiving induction with either antithymocyte globulin or basiliximab. Transplant Proc 38 (2006) 1307
14. Tchervenkov J.I., Tzimas G.N., Cantarovich M., et al. The impact of Thymoglobulin on renal function and calcineurin inhibitor initiation in recipients of orthotopic liver transplant: a retrospective analysis of 298 consecutive patients. Transplant Proc 36 (2004) 1747
15. Szczech L.A., Berlin J.A., Aradhye S., et al. Effect of anti-lymphocyte induction therapy on renal allograft survival: a meta-analysis. J Am Soc Nephrol 8 (1997) 1771
16. Szczech L.A., Berlin J.A., and Feldman H.I. The effect of antilymphocyte induction therapy on renal allograft survival. A meta-analysis of individual patient-level data. Anti-Lymphocyte Antibody Induction Therapy Study Group. Ann Intern Med 128 (1998) 817
17. Racusen L.C., Solez K., Colvin R.B., et al. The Banff 97 working classification of renal allograft pathology. Kidney Int 55 (1999) 713